<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00228436</url>
  </required_header>
  <id_info>
    <org_study_id>AFX01-04</org_study_id>
    <secondary_id>2005-002218-39</secondary_id>
    <nct_id>NCT00228436</nct_id>
  </id_info>
  <brief_title>Safety, PD &amp; PK of Multiple Doses of Peginesatide for Anemia in Chronic Kidney Disease Patients</brief_title>
  <official_title>A Phase 2, Open-label, Multi-center, Sequential Dose Finding Study of the Safety, Pharmacodynamics, and Pharmacokinetics of Multiple Doses of Subcutaneously Administered Peginesatide in Chronic Kidney Disease Patients Not on Dialysis and Not on Erythropoiesis Stimulating Agent (ESA) Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Affymax</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Affymax</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to evaluate the safety, pharmacodynamics (PD), and
      pharmacokinetics (PK) of multiple subcutaneous injections of peginesatide in participants
      with chronic kidney disease (CKD) not on dialysis who had not received erythropoiesis
      stimulating agent (ESA) treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a Phase 2, dose finding study designed to evaluate peginesatide treatment of
      participants with CKD not on ESA treatment. The objective was to determine the range of doses
      of peginesatide administered subcutaneously once every 4 weeks (Q4W) that increased and
      maintained hemoglobin at 11 to 13 g/dL.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">November 2007</completion_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants who achieved a target hemoglobin response during the study.</measure>
    <time_frame>25 weeks</time_frame>
    <description>A target hemoglobin response is defined as a hemoglobin increase of ≥ 1.0 gram per deciliter (g/dL) from baseline and a hemoglobin value ≥ 11.0 g/dL during the study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events and serious adverse events</measure>
    <time_frame>25 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters</measure>
    <time_frame>25 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with hemoglobin values in the range of 11.0 to 13.0 g/dL throughout the study.</measure>
    <time_frame>25 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">139</enrollment>
  <condition>Anemia</condition>
  <condition>Chronic Kidney Disease</condition>
  <condition>Chronic Renal Failure</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Peginesatide starting dose of 0.05 milligram per kilogram (mg/kg) administered subcutaneously (SC) once every 4 weeks (Q4W) for a total of 6 doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Peginesatide starting dose of 0.075 mg/kg administered SC Q4W for a total of 6 doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Peginesatide starting dose of 0.025 mg/kg administered SC Q4W for a total of 6 doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Peginesatide starting dose of 0.05 mg/kg administered intravenously (IV) Q4W for a total of 6 doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Peginesatide starting dose of 0.025 mg/kg administered SC once every 2 weeks (Q2W) for a total of 12 doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Peginesatide starting dose of 0.0375 mg/kg administered SC Q2W for a total of 12 doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Peginesatide fixed starting dose of 4 mg administered SC Q4W for a total of 6 doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Peginesatide fixed starting dose of 3 mg administered SC Q4W for a total of 6 doses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>peginesatide</intervention_name>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_label>Cohort 6</arm_group_label>
    <arm_group_label>Cohort 7</arm_group_label>
    <arm_group_label>Cohort 8</arm_group_label>
    <other_name>Omontys</other_name>
    <other_name>Hematide</other_name>
    <other_name>AF37702 Injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participant is informed of the investigational nature of this study and has given
             written, witnessed informed consent in accordance with institutional, local and
             national guidelines;

          -  Males or females ≥ 18 and ≤ 85 years of age. Pre-menopausal females (with the
             exception of those who are surgically sterile) must have a negative pregnancy test at
             screening; those who are sexually active must practice an adequate form of
             contraception for at least 4 weeks prior to study start, and must be willing to
             continue contraception for at least 4 weeks after the last dose of study drug;

          -  Chronic kidney disease stage 3 or 4 (estimated Glomerular filtration rate [GFR] of
             15-60 mL/min within 28 days prior to study drug administration) and not expected to
             begin dialysis for at least 12 weeks;

          -  Two hemoglobin values of ≥ 9.0 and &lt; 11.0 g/dL within 14 days prior to study drug
             administration, including at least one of the values drawn within 7 days prior to
             study drug administration;

          -  One serum ferritin level ≥ 100 micrograms per liter (μg/L) and transferrin saturation
             ≥ 20 % within 4 weeks prior to study drug administration;

          -  One serum or red cell folate level above lower limit of normal within 4 weeks prior to
             study drug administration;

          -  One vitamin B12 level above lower limit of normal within 4 weeks prior to study drug
             administration;

          -  Weight ≥ 45 kg within 4 weeks prior to study drug administration;

          -  One white blood cell count ≥ 3.0 x 10^9/L within 4 weeks prior to study drug
             administration; and

          -  One platelet count ≥ 100 x 10^9/L within 4 weeks prior to study drug administration.

        Exclusion Criteria:

          -  Prior treatment with any erythropoiesis stimulating agent in the 12 weeks prior to
             study drug administration;

          -  Any prior treatment with Eprex®;

          -  Known intolerance to any erythropoiesis stimulating agent;

          -  History of antibodies to any erythropoiesis stimulating agent or history of pure red
             cell aplasia;

          -  Prior hemodialysis or peritoneal dialysis treatment;

          -  Known intolerance to parenteral iron supplementation;

          -  Red blood cell transfusion within 12 weeks prior to study drug administration;

          -  Hemoglobinopathy [e.g., homozygous sickle-cell disease (sickle-cell trait does not
             exclude patient), thalassemia of all types, etc.];

          -  Known hemolysis;

          -  Chronic, uncontrolled, or symptomatic inflammatory disease (e.g., rheumatoid
             arthritis, systemic lupus erythematosus, etc.);

          -  C Reactive Protein (CRP) greater than 30 mg/L within the 4 weeks prior to study drug
             administration;

          -  Febrile illness within 7 days prior to study drug administration;

          -  Uncontrolled or symptomatic secondary hyperparathyroidism;

          -  Poorly controlled hypertension within 4 weeks prior to study drug administration, per
             Investigator's clinical judgment (e.g. systolic ≥ 170mm Hg, diastolic ≥ 100 mm Hg on
             repeat readings);

          -  Epileptic seizure in the 6 months prior to study drug administration;

          -  Chronic congestive heart failure (New York Heart Association Class IV);

          -  High likelihood of early withdrawal or interruption of the study;

          -  Evidence of malignancy within the past 5 years (except non-melanoma skin cancer which
             is not an exclusion criterion);

          -  Life expectancy &lt; 12 months;

          -  Anticipated elective surgery during the study period; and

          -  Previous exposure to any investigational agent within 6 weeks prior to administration
             of study drug or planned receipt during the study period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Affymax</last_name>
    <role>Study Director</role>
    <affiliation>Affymax, Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Białystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Gdansk</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facilities</name>
      <address>
        <city>Kraków</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Łódź</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Coventry</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Croydon</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Derby</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Leicester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facilities</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Salford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Swansea</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 27, 2005</study_first_submitted>
  <study_first_submitted_qc>September 27, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2005</study_first_posted>
  <last_update_submitted>December 19, 2012</last_update_submitted>
  <last_update_submitted_qc>December 19, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 21, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>anemia</keyword>
  <keyword>chronic kidney disease</keyword>
  <keyword>CKD</keyword>
  <keyword>chronic renal failure</keyword>
  <keyword>CRF</keyword>
  <keyword>dialysis</keyword>
  <keyword>erythropoietin</keyword>
  <keyword>EPO</keyword>
  <keyword>erythropoiesis stimulating agent</keyword>
  <keyword>ESA</keyword>
  <keyword>Hematide™</keyword>
  <keyword>hemoglobin</keyword>
  <keyword>Hb</keyword>
  <keyword>Hgb</keyword>
  <keyword>Omontys</keyword>
  <keyword>peginesatide</keyword>
  <keyword>red blood cell</keyword>
  <keyword>red blood cell production</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematinics</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

